ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

CMSH China Medical

52.00
0.00 (0.00%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
China Medical LSE:CMSH London Ordinary Share KYG211081164 ORD USD0.005 (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 52.00 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

China Medical Share Discussion Threads

Showing 26 to 47 of 450 messages
Chat Pages: Latest  6  5  4  3  2  1
DateSubjectAuthorDiscuss
20/5/2009
12:28
Gone XD today, explains most of the drop today.

Good choice i think Azalea - reasonable p/e, big cash pile, 30%+ growth

Ought to do well.

i dont think many people are aware of this, although the usual 'under the radar' statement seems to be dragged out for every share these days.

stegrego
19/5/2009
12:23
nice report here - gives target price of 255p.
stegrego
13/5/2009
12:39
No


The forecast here was for 17.46p - they actually did 21p....

Thats only a penny off next years forecast.

stegrego
13/5/2009
11:13
is this stock isa-able?
oilgetmecoat
13/5/2009
08:34
Only a couple of % id have thought, but to be honest, the divi on these sort of stocks is just an extra bonus for me rather than the reason to buy.
stegrego
13/5/2009
08:32
stegrego

agreed and the level of divi was a pleasant surprise especially for a chinese company. Regarding bsst what do you reckon the yield will be at 17p.

lonrho
13/5/2009
08:25
Just the 2 - JTC and WCC - dont like to ramp across mulitple boards. In fact dont like to ramp at all, just giving people a chance to research.

Lovely results today - if this was a UK co and a normal market, it would be 400p+.

stegrego
13/5/2009
08:21
stegrego

good to see you are spreading the word on some of my favourite boards.

lonrho
13/5/2009
07:28
can i just check my logic?.....

sales growth of 40%
gross profit growth of 33%
EPS up 50% to $0.316 (21p)
dividend of $0.15 (10p) a yield of 7.1%
so......
a current p/e of 6.66 and a prospective p/e of 5.03 based on fcast of $41.70 or 27.8p (digital look data) for 2009.

Wow, this is way undervalued...........and you get a drug pipeline in free of charge.

andysburns
11/5/2009
10:05
stegrego

ok I will keep quiet, but talking of under the radar chinese shares have you looked at china biodiesel (cbi) much riskier but a huge discount to tangible net assets.

lonrho
11/5/2009
09:09
I agree is overlooked.

Ive got a few, prior to results. Will see how it goes.

Any size buy moves the price and you cant get a direct online quote.

Hoepfully results will draw attention and the share will take off (not before ive bought more if the results are good though hopefully!)

Please dont ramp this until after results ;)

stegrego
07/5/2009
11:13
Results out 13th may. This company has been totally overlooked in recent rises but is growing at over 30% per year, has lots of cash in the bank and is on a prospective 2009 p/e of about 4 with a dividend yield of about 8%.
lonrho
28/10/2008
10:51
Interested to find out more about this company that came up as one of the top 9 listed companies in london showing high ROCE and low p/e, positive DY and cashflow and historic and forecast growth rates of 20%+.
promethean
31/7/2008
12:30
RNS Number : 3098A
China Medical Systems Holdings Ltd
31 July 2008


China Medical System has been approved to commence the Phase 2 clinical trial for a novel cancer treatment

China Medical System Holdings Ltd. (AIM: CMSH), the integrated and profitable Chinese pharmaceutical company is pleased to announce that it has received approval from the Chinese State Food and Drug Administration (SFDA) to commence the Phase II clinical trial for CMS024-02 (Tyroservatide), an in-house developed novel drug for the treatment of non-small cell lung cancer, one of the most common malignant tumours in China.

This marks a positive development for CMS024-02 following the submission of Phase II clinical trial application to SFDA in March 2007. The results of the Phase I clinical trial have demonstrated that CMS024-02 is safe and well tolerated by patients. The Company plans to initiate the Phase II Clinical Trial Protocol in the second half of 2008.

Mr Lam Kong, Chairman of China Medical System Holdings Ltd., said: 'We are very pleased with the approval of CMS024-02 for further clinical trial from SFDA. It is the second novel drug we have developed in house to Phase II trial. While our sales and marketing business is still growing, we are pleased that we have also made great progress in our R&D pipeline.'

papalpower
25/7/2008
07:09
Dorset - Evo's the house broker not seymour.

Good update ;-) What effect it has on the share price in these markets is anybodys guess.

pezza2
25/7/2008
07:04
RNS Number : 7900Z
China Medical Systems Holdings Ltd
25 July 2008


TRADING UPDATE

China Medical System Holdings Ltd. (AIM: CMSH), the integrated and profitable Chinese pharmaceutical company is pleased to announce a trading update for the first six months ending 30 June 2008.

The Company is pleased to report that trading for the first half of 2008 was in line with market expectations, with half year revenues anticipated to be approximately US$33.8 million. This represents year on year growth of approximately 41%. Sales for the first 6 months of 2007 amounted to US$23.9 million.

Historically the second half of the year has been the stronger period of CMS's financial year. Moreover, with the addition of 2 new products to the portfolio in 2008, the Board anticipates that sales in the second half of 2008 will once more exceed those of the first half.

Mr Lam Kong, Chairman of China Medical System Holdings Ltd. said, 'CMS has continued to make great progress in boosting the sales of existing products and in-licensing new products to expand revenue source, and I am very pleased by the 41% growth in sales from last year.'

papalpower
23/7/2008
13:56
No idea :)
papalpower
23/7/2008
13:55
pp, are seymour the house broker?
dorset64
23/7/2008
13:37
China Medical System 3,5 (BUY) - Initiating coverage

CMSH.L 126.5p (Target price 193p) Market Cap: £59.8m

CMS benefits strongly from its distinctive business model and own sales force. We expect net profits to grow by at least 35% per annum in the next three years. We initiate coverage with a BUY recommendation and a target price of 193p.

Zhining Xu
Research Analyst
Seymour Pierce

papalpower
04/7/2008
00:52
Its true mom.

The trouble is most people have no clue as so just get ramped into the wrong ones by the rampers.

papalpower
04/7/2008
00:47
PapalPower - 3 Jul'08 - 12:17 - 23 of 24


'Nice and blue, don't know why people cannot make money from Chinese stocks, its all about knowing which ones will go up, and which ones down.'


Recorded for future reference.

myoldmate
03/7/2008
12:17
Nice and blue, don't know why people cannot make money from Chinese stocks, its all about knowing which ones will go up, and which ones down.

LOL :)

papalpower
Chat Pages: Latest  6  5  4  3  2  1

Your Recent History

Delayed Upgrade Clock